Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; 3 of the 46 sources its claims cite were checked for support.
Abstract
PURPOSE: This study investigates the possible effect and central mechanism of novel antidiabetic medication sodium glucose transporter-2 (SGLT-2i) on the cardiovascular activity. MATERIAL AND METHODS: Thirty-four normal male C57BL/6 mice were randomly assigned to 2 groups to receive single Dapagliflozin (1.52mg/kg) dose via intragastric gavage or a comparable dose of saline. Glycemic level (BG), blood pressure (BP) and heart rate (HR) were measured 2 hours after administration of the respective treatments. Immunohistochemical tests were performed to determine the effect of SGLT-2i on neural localization of SGLT-2 and c-Fos, a neural activator. The distributional relationships of SGLT-2 and c-Fos were examined by immunofluorescence. RESULTS: Administration of SGLT-2i significantly decreased BP but did not affect the HR. There was no difference in BG between the two groups. Results showed that SGLT-2 was localized to specific regions involved in autonomic control. Expression of c-Fos was significantly higher in major critical nuclei in the aforementioned regions in groups treated with Dapagliflozin. CONCLUSION: This study demonstrates that SGLT-2 is expressed in CNS tissues involved in autonomic control and possibly influence cardiovascular function. Dapagliflozin influences central autonomic activity via unidentified pathways by inhibiting central or peripheral SGLT-2. These results provide a new concept that sympathetic inhibition by SGLT-2i can be mediated by central autonomic system, a mechanism that explains how SGLT-2i improves the cardiovascular function.
Overview
CoChat Summary
TL;DR
In normal male C57BL/6 mice, a single intragastric dapagliflozin dose (1.52 mg/kg) lowered systolic and diastolic blood pressure at 2 h without significantly changing heart rate or blood glucose, while increasing c-Fos in autonomic nuclei. The authors localize SGLT-2 in hypothalamus, amygdala, periaqueductal gray, and nucleus of the solitary tract, and propose central SGLT-2 inhibition activates autonomic circuits, especially PVN, to regulate cardiovascular activity.
Key findings
- Dapagliflozin did not significantly change blood glucose at 2 h versus saline (9.5 ± 0.163 vs 9.6 ± 0.163 mmol/l, P > 0.05); values at 1 h and 2 h were lower in dapagliflozin but not statistically significant (1 h: 8.9 ± 0.331 vs 9.1 ± 0.331 mmol/l; 2 h: 7.9 ± 0.229 vs 8.5 ± 0.229 mmol/l; P > 0.05).
- At 2 h after gavage, systolic BP was 111.265 ± 3.964 mmHg in dapagliflozin vs 128.932 mmHg in control, and diastolic BP was 88.289 ± 3.971 vs 105.236 ± 1.756 mmHg (both P < 0.05); heart rate did not differ significantly (389.147 ± 16.018 vs 435.403 ± 6.188, P > 0.05).
- SGLT-2 was abundantly expressed in brain regions related to autonomic control, including hypothalamus, amygdala, periaqueductal gray (PAG), and nucleus of the solitary tract (NTS).
- c-Fos expression was significantly higher after dapagliflozin in many autonomic nuclei, including PVN (78.000 ± 3.873 vs 30.000 ± 4.235), NTS (95.500 ± 3.704 vs 50.000 ± 3.661), PAG (115.833 ± 3.229 vs 71.000 ± 4.844), and LC (74.667 ± 5.451 vs 34.500 ± 5.359; all P < 0.05).
Methods
- Thirty-four normal male C57BL/6 mice were randomized to dapagliflozin (1.52 mg/kg, n = 17) or saline (n = 17) by intragastric gavage; blood glucose was measured before, every 15 min for the first hour, and 2 h after administration. The paper also reports 14 male mice randomized for BP and HR measurement at 0, 1, and 2 h using a non-invasive volume-pressure-sensing monitor.
- Brains were processed for immunohistochemistry for SGLT-2 and c-Fos, Nissl staining, and dual immunofluorescence; Fos-immunoreactivity was quantified blinded based on the Allen mouse brain atlas.
- Statistical analysis used two-way ANOVA with Sidak multiple comparison tests for Fos-IR, repeated-measures ANOVA with Sidak tests for blood glucose, and repeated-measures ANOVA with Tukey tests for BP and HR; P ≤ 0.05 was considered significant.
Limitations
- Stated: the authors did not explore the dynamics of SGLT-2i in the brain due to technical limitations, and they note that more precise techniques such as radiography or fluorescent labeling are needed in future studies.
- Stated: urine volume was not monitored, and the authors note that other neural pathways may exist through which dapagliflozin activates neurons in autonomic areas.
- Evident from the text: the study used normal mice rather than a T2DM model, tested only an acute single dose with a 2-h observation window, and did not directly establish whether the cardiovascular effects are caused by central versus peripheral SGLT-2 inhibition.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
3 Valid · 1 Not valid · 22 Not checked · 53 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“existing evidence argue that SGLT-2i possess cardiovascular benefits.3”
- Also stated in: § Introduction · boosted
“existing clinical trials have demonstrated the beneficial effects of SGLT-2i to the cardiovascular system in reducing the incidence of cardiovascular events”
§ Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice > Introduction
What the sources say
- Supportedcites [3] Dewan, 2020, Eur J Heart Fail source
The Introduction (p. 1) states that in DAPA-HF, dapagliflozin (an SGLT2 inhibitor) gave a 26% lower risk of worsening HF event or cardiovascular death versus placebo, and the Results/Discussion sections report this benefit as consistent across the LVEF spectrum and in patients with and without diabetes, with larger absolute benefit at lower LVEF. That is exactly the substance of the unqualified background statement that SGLT-2 inhibitors possess cardiovascular benefits, so the broad paraphrase is supported by our copy. The one qualifier worth noting is that the benefit demonstrated here is for dapagliflozin in HFrEF (LVEF ≤40%); the Discussion explicitly says whether SGLT2 inhibition extends to mid-range/mildly reduced and preserved EF 'remains to be determined' and calls prior HFpEF subgroup signals 'far from conclusive'. (LLM, conf=0.82)
- Not checked yetcites [7] Heerspink, 2016, Circulation source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no difference in BG between the two groups.”
- Also stated in: § Glycemic Dynamic and Change of BP and HR After Intragastric Gavage with SGLT-2i · plain
“our results showed no significant differences in blood glucose levels between the experimental group and the control group in 2 hours after administration”
§ Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Glycemic Dynamic and Change of BP and HR After Intragastric Gavage with SGLT-2i · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Expression of c-Fos was significantly higher in major critical nuclei in the aforementioned regions in groups treated with Dapagliflozin.”
- Also stated in: § c-Fos Expression Distribution in the Brain After Administration with SGLT-2i · plain
“high c-Fos expression occurred hypothalamus, amygdala and periaqueductal gray, and significantly higher when compared to the control group”
§ Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § c-Fos Expression Distribution in the Brain After Administration with SGLT-2i · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“SGLT-2 was localized to specific regions involved in autonomic control.”
- Also stated in: § SGLT-2 Distribution in the Brain · plain
“SGLT-2 was abundantly expressed in the brain, from the forebrain to brainstem, precisely in the hypothalamus, amygdala, periaqueductal gray (PAG), and the nucleus of the solitary tract (NTS) related to autonomic control”
§ Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § SGLT-2 Distribution in the Brain · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Me, VMH which according to previous studies showed a relationship with glucose sensing, demonstrated increased c-Fos expression when compared to control group.”
§ Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice > Results > c-Fos Expression Distribution in the Brain After Administration with SGLT-2i
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 79 claims and to verify the 43 references still open.
- It may state two separate claims as one. 19
- The quote only partly states this claim. 3
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain expression of SGLT2 is lower than SGLT1, and it occurs mainly in the microvessels of the blood-brain barrier, but also in the amygdala, hypothalamus, periaqueductal gray (PAG), and in the dorsomedial medulla – the nucleus of the solitary tract (NTS) [22,23].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [23]
Experimental — accuracy not yet measured
Citations
Cites
Expression of c- fos Protein in Brain: Metabolic Mapping at the Cellular Level
Sagar, S. M., Sharp, F. R., & Curran, T. (1988) · Science · doi:10.1126/science.3131879 · Cited by 1,925
The Central Autonomic Network: Functional Organization, Dysfunction, and Perspective
BENARROCH, E. E. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62272-1 · Cited by 1,534
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
The use of c-fos as a metabolic marker in neuronal pathway tracing
Dragunow, M., & Faull, R. (1989) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(89)90150-7 · Cited by 1,416
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Circadian rhythm disruption and mental health
Walker, W. H., Walton, J. C., DeVries, A. C., & Nelson, R. J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0694-0 · Cited by 1,030
Stimulus-transcription coupling in neurons: role of cellular immediate-early genes
Morgan, J. I., & Curran, T. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90096-9 · Cited by 969
c-Fos and Related Immediate Early Gene Products as Markers of Activity in Neuroendocrine Systems
Hoffman, G. E., Smith, M. S., & Verbalis, J. G. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1006 · Cited by 715
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
The Fos family of transcription factors and their role in tumourigenesis
Milde-Langosch, K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.008 · Cited by 583
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“It is possible that SGLT2 receptors also exert a cardioprotective effect through central mechanisms by directly influencing cardiovascular regulation and autonomic pathways, including the paraventricular nucleus of the hypothalamus, the nucleus of the solitary tract, and the periaqueductal gray [23].”
BackgroundInfluentialImpact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115863 · Cited by 110
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 122
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
Self-citationAnti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Heimke, M., Lenz, F., Rickert, U., Lucius, R., & Cossais, F. (2022) · Cells · doi:10.3390/cells11193107 · Cited by 78
Metadata
- Authors
- Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L.
- Affiliations
- Fudan University (CN)
- Corresponding author
- Zhou, Ligang
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-08
- Volume
- Volume 13
- Pages
- 2781-2799
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC7425107
- OpenAlex
- W3046924930
- Semantic Scholar
- 0db05fd853b8a8a9224b44a60db3a4fc53e743a1
- Cited by
- 97
- References
- 66
- Citations by year
- 2026: 10 · 2025: 27 · 2024: 18 · 2023: 21 · 2022: 11 · 2021: 8 · 2020: 2
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Natural Science Foundation of Shanghai (ZHYY-ZXYJHZX-2-201712, PWR12014-06, PWYgy-2018-08, 21675034, 19ZR1447500, 81370932)
- National Natural Science Foundation of China (PWYgy-2018-08, 81370932, PWR12014-06, 19ZR1447500, PWZzk2017-03, ZHYY-ZXYJHZX-2-201712, 21675034)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- dapagliflozin, SGLT2 inhibitors, central nervous system, autonomic nervous system, c-fos, blood pressure, heart rate, GLUT2, cardiovascular effects, antidiabetic drugs, sympathoinhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.